Evaluating the Accuracy of Breast Cancer and Molecular Subtype Diagnosis by Ultrasound Image Deep Learning Model

Xianyu Zhang1†, Hui Li1†, Chaoyun Wang2†, Wen Cheng3†, Yuntao Zhu2, Dapeng Li4, Hui Jing3, Shu Li3, Jiahui Hou3, Jiaying Li1, Yingpu Li1, Yashuang Zhao*, Hongwei Mo²* and Da Pang1*

1Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China, 2Harbin Engineering University Automation College, Harbin, China, 3Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, China, 4Department of Epidemiology, Harbin Medical University, Harbin, China, 5Prenatal Diagnosis Center, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Background: Breast ultrasound is the first choice for breast tumor diagnosis in China, but the Breast Imaging Reporting and Data System (BI-RADS) categorization routinely used in the clinic often leads to unnecessary biopsy. Radiologists have no ability to predict molecular subtypes with important pathological information that can guide clinical treatment.

Materials and Methods: This retrospective study collected breast ultrasound images from two hospitals and formed training, test and external test sets after strict selection, which included 2,822, 707, and 210 ultrasound images, respectively. An optimized deep learning model (DLM) was constructed with the training set, and the performance was verified in both the test set and the external test set. Diagnostic results were compared with the BI-RADS categorization determined by radiologists. We divided breast cancer into different molecular subtypes according to hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression. The ability to predict molecular subtypes using the DLM was confirmed in the test set.

Results: In the test set, with pathological results as the gold standard, the accuracy, sensitivity and specificity were 85.6, 98.7, and 63.1%, respectively, according to the BI-RADS categorization. The same set achieved an accuracy, sensitivity, and specificity of 89.7, 91.3, and 86.9%, respectively, when using the DLM. For the test set, the area under the curve (AUC) was 0.96. For the external test set, the AUC was 0.90. The diagnostic accuracy was 92.86% with the DLM in BI-RADS 4a patients. Approximately 70.76% of the cases were judged as benign tumors. Unnecessary biopsy was theoretically reduced by 67.86%. However, the false negative rate was 10.4%. A good prediction effect was shown for the molecular subtypes of breast cancer with the DLM. The AUC were 0.864, 0.811, and 0.837 for the triple-negative subtype, HER2 (+) subtype and HR (+) subtype predictions, respectively.
INTRODUCTION

Breast cancer is the most common malignant tumor in women in China (1, 2). Breast ultrasound is more suitable for tumor discovery in Asian women considering the higher breast density (3, 4) and the younger age at diagnosis (5, 6). Patients with Breast Imaging Reporting and Data System (BI-RADS) 4a or higher findings are usually recommended to undergo core needle biopsy or surgery. BI-RADS has a wide range of possibilities to predict the presence of malignancies, but its false positive findings lead to unnecessary biopsies in a large number of individuals without breast cancer (7).

The combination of deep learning (8) and large datasets has shown good performance in the diagnosis of many diseases, including cancer (9–12). The deep learning model (DLM) takes the original image pixels and corresponding category labels in medical image data as inputs and does not require manual design features required by traditional methods but automatically learns features related to category classification (13).

Based on receptor status, breast cancers are divided into five subtypes (14). If the molecular subtype is identified before surgery, we can determine whether the patient is suitable for neoadjuvant treatment and which scheme should be more efficient. However, currently, we cannot obtain subtype information through traditional ultrasound examinations.

In addition to the differentiation of benign and malignant breast tumors from ultrasound images, previous studies have focused on the correlation between imaging features and molecular subtypes. Breast cancers with the triple-negative subtype were more likely to be associated with circumscribed margins and were less associated with calcifications (15–18). Human epidermal growth factor receptor 2 (HER2) (+) breast cancers usually show enhanced posterior acoustics on ultrasound images (15, 17). Tumors with posterior shadowing are often found in hormone receptor (HR) (+) HER2 (−) breast cancers (16, 19, 20). In addition, echogenic halos were frequently present in the HR (+) HER2 (−) subtype (17, 20). Due to the various imaging features of different subtypes, there is potential to predict molecular subtypes with DLM by analyzing only the ultrasound images.

In this study, we constructed a DLM based on ultrasound images. We obtained a higher accuracy for breast tumor diagnosis with the DLM than with radiologists. We obtained a good prediction for tumor molecular subtypes, which may provide more choices for therapy.

**Conclusion:** This study showed that the DLM was highly accurate in recognizing breast tumors from ultrasound images. Thus, the DLM can greatly reduce the incidence of unnecessary biopsy, especially for patients with BI-RADS 4a. In addition, the predictive ability of this model for molecular subtypes was satisfactory, which has specific clinical application value.

**Keywords:** breast cancer, deep learning, ultrasound, cancer diagnosis, molecular subtype

MATERIALS AND METHODS

This study was approved by the Institutional Review Board of Harbin Medical University Cancer Hospital. Because of its retrospective nature, the study was exempt from obtaining informed consent from patients.

**Datasets**

We obtained original ultrasound images for the training and testing datasets from the breast image database of Harbin Medical University Cancer Hospital (a total of 17,226 images from 2,542 patients). All patients underwent surgical treatment with definitive pathological results. The cohort selection flowchart is shown in Figure 1. Patients in the external test set were enrolled from The First Affiliated Hospital of Harbin Medical University and were selected with the same criteria as those for the training and test sets. Exclusion criteria for the datasets are described in the Supplementary Material.

We selected ultrasound images of breast cancer patients with corresponding pathological results. We excluded tumors with incomplete immunohistochemistry results and then separated the tumors into molecular subtypes. Data on estrogen receptor (ER) and progesterone receptor (PR) expression were collected. Patients with positivity for either or both receptors were defined as being HR positive. According to the expression of two indicators, HR and HER2, we regrouped patients into three molecular subtypes: HER2 (+) subtype, HR (+) subtype and triple-negative subtype. HER2 (+) subtype = HR (+) HER2 (+) or HR (−) HER2 (+); HR (+) subtype = HR (+) HER2 (−); triple-negative subtype = HR (−) HER2 (−).

In Figure 2, we listed some samples of breast ultrasound images from the datasets, which were presented by classification of benign and malignant tumors and molecular subtypes.

The training and test sets were formed by a random sampling method at a ratio of 4:1. The compositions of these sets are shown in Figure 1. It is noteworthy that within the training set, we redivided it into a new training set and a validation set for model tuning and training at a ratio of 4:1. The optimal model obtained was tested with the test set and the external test set.

**Development of the DLM**

All images in the datasets were 8-bit and 3-channel images, so they could be used as training set and test set images to fine-tune the deep convolutional neural network (DCNN) directly. **Supplementary Figure 1** shows the whole process of breast ultrasound image analysis.
To obtain a better deep learning effect, the necessary image preprocessing algorithm was used to improve the image quality. In the image preprocessing of the Supplementary Material, we specifically described how to carry out preprocessing of breast ultrasound images.

Considering the amount of data compared with the depth of deep learning, we used data enhancement to enhance the diversity and generalization of the data. We used data enhancement in the Keras model, which could enhance the real-time data with the help of a central processing unit (CPU) during training. Due to the particularity of the ultrasound image data, we used four kinds of random operations to enhance the data: vertical rotation, horizontal rotation, center rotation, and scale reduction.

Because the data had enough high-quality samples after preprocessing and expansion, we used the deep learning Keras framework to transfer and fine-tune the Xception network, making it a network that could extract features for breast ultrasound images (21). The Xception convolution neural network (CNN) has trained more than 1.2 million images from the ImageNet large-scale vision recognition challenge (ILSVRC) knowledge base.

The structure of the Xception model mainly consisted of a convolutional layer and a fully connected classification layer. Figure 3 shows the structure diagram of our model training,
which mainly adopted the transfer learning method to train the model. CNN-1 represented the training model on the ImageNet dataset and outputted 1,000 classification results. The CNN-2 model was obtained through transfer learning of the CNN-1 model and used for the classification of benign and malignant breast tumors by ultrasound images. The specific model training method was to freeze the convolutional layer parameters of CNN-2 and then train the fully connected layer of the CNN-2 model. After the training was stable, we defrosted the convolutional layer for retraining to achieve the best effect. CNN-3 was a classification model of molecular subtypes, which was acquired from the transfer learning of the CNN-2 model. Two specific training parameters are shown in the Supplementary Material.

Statistical Analysis

Evaluation of the DLM was performed with R version 3.5.1. For binary classification in discriminating breast cancer patients from controls, a classification matrix (caret version 6.0–80) and the receiver operating characteristic (ROC) curve (pROC version 1.13.0) were generated to visualize the diagnostic ability of the DLM. For the triple classification of the three molecular subtypes, a classification matrix and the ROC curve using a one-vs-all approach (multiROC version 1.1.1) were generated. The area under the curve (AUC), accuracy, sensitivity, and specificity were calculated to compare the predictive performance between the DLM and BI-RADS classification systems in the test and external test sets. $P < 0.05$ was considered to indicate a statistically significant difference. Moreover, the calculation of sample size is shown in the Supplementary Material.

RESULTS

Cohort Composition

We divided the ultrasound images collected from Harbin Medical University Cancer Hospital into two sets (Figure 1). The training set was composed of 2,822 images, including 1,786 images from 1,217 patients with malignant tumors and 1,036 images from 603 patients with benign tumors. The test set was composed of 707 images, including 447 images from 392 patients with malignant tumors and 260 images from 228 patients with benign tumors. After applying the same exclusion criteria, external test set images were collected from The First Affiliated Hospital of Harbin Medical University, including 93 images from 38 patients with malignant tumors and 117 images from 45 patients with benign tumors.

Two datasets were used for molecular subtype prediction (Figure 1). The training set consisted of 212 images from 149 HER2 (+) subtype patients, 588 images from 417 HR (+) subtype patients and 186 images from 118 triple-negative subtype patients. The test set comprised 54 images from 47 HER2 (+) subtype patients, 148 images from 135 HR (+) subtype patients and 47 images from 40 triple-negative subtype patients.

Performance in Diagnosis

The DLM was more accurate (0.897, 95% CI: 0.872–0.918) than ultrasound doctors (0.856, 95% CI: 0.828–0.881) ($P = 0.024$) (Tables 1, 2). The doctors used the malignant probability and BI-RADS system to determine positive ultrasound findings. For sensitivities, 91.3 and 98.7% ($P < 0.001$) were achieved for the DLM and BI-RADS systems, respectively. However, the

![FIGURE 2](image_url)
specificity of the DLM (86.9%) was significantly higher than that of BI-RADS (63.1%) \((P < 0.001)\). This result indicates that the DLM may reduce the unnecessary biopsy of false positive findings with the BI-RADS system. For the test set, the AUC was 0.96. For the external test set, the AUC was 0.90 (Figure 4). These results suggest that the DLM has good performance in breast cancer diagnosis.

### Reducing Unnecessary Biopsy

Each ultrasound image had corresponding BI-RADS, DLM, and pathological results. The proportion of all patients with BI-RADS 4a judged as benign (70.76%) by the DLM was greater than that judged as malignant (29.24%) (Figure 5A). This result indicated that 70.76% of BI-RADS 4a patients did not need surgery when diagnosed using the DLM. The diagnostic accuracy for BI-RADS 4a patients reached 92.86%, and unnecessary biopsy was reduced by 67.86%, with a false negative rate of 10.4% for the DLM (Figure 5B). These findings suggest that the DLM can greatly reduce the incidence of unnecessary
biopsy, especially for BI-RADS 4a patients with a low false negative rate.

**Molecular Subtype Prediction**

The DLM can be used not only in the diagnosis of breast cancer but also in the prediction of molecular subtypes. From the results of the triple classification, the triple-negative subtype reached the highest AUC of 0.864. The AUC of the HER2 (+) subtype was 0.811, and the AUC of the HR (+) subtype was 0.837 (Figure 6). Accuracy of the HR (+) subtype (85.14%) was significantly higher than that of the HER2 (+) subtype (50%) and triple-negative subtype (53.19%) (Supplementary Table 1).

|                      | Test set | External test set |
|----------------------|----------|-------------------|
|                      | BI-RADS  | DLM               |
| Accuracy             | 0.856    | 0.897             | –                  |
| Sensitivity          | 0.987    | 0.913             | <0.001             |
| Specificity          | 0.631    | 0.869             | <0.001             |
| Positive predictive value | 0.821   | 0.923             | <0.001             |
| Negative predictive value | 0.965   | 0.853             | <0.001             |
| Kappa                | 0.666    | 0.779             | –                  |

**DISCUSSION**

We successfully established a DLM for breast cancer diagnosis and molecular subtype prediction based on ultrasound images. The accuracy of the DLM in the diagnosis of breast cancer was higher than that of BI-RADS, and the DLM performed well in both the test set and external test set. The DLM can apparently reduce unnecessary biopsy for patients with BI-RADS 4a. In the predictive results of the DLM for the molecular subtypes of breast cancer, we could see that its performance for various subtypes was ideal, and there were no significant disparities among them.

In many studies of cancer diagnosis, the accuracy of DLMs is higher than that of radiologists. Li et al. successfully developed a DCNN model for the diagnosis of thyroid cancer with ultrasound images. The accuracy was 89.8% with the DCNN model vs. 78.8% with radiologists (22). To classify invasive adenocarcinomas from preinvasive lesions, Wang et al. (23) developed a CNN model. The accuracy of the model (84%) was higher than that of three radiologists (radiologist 1: 80.2%; radiologist 2: 80.7%; and radiologist 3: 81.7%). He et al. used a CNN to predict the local recurrence of giant cell bone tumors. The accuracy of the CNN model was 75.0%, while the accuracy of radiologists was 64.3% (24). Our study had similar results. The DLM was more accurate (0.897, 95% CI: 0.872–0.918) than radiologists (0.856, 95% CI: 0.828–0.881) ($P = 0.024$). In summary, the DLM performed well and has the potential to provide better diagnostic results than radiologists.

At present, there are few studies on the diagnosis of breast cancer with DLMs based on ultrasound images. In recent studies, researchers used different DLMs to diagnose breast tumors on ultrasound images, and the one that performed best was selected...
The purpose of these studies was to develop only a DLM for the classification of malignant and benign masses (25–29). In our study, we sought to develop a DLM not only for classifying masses but also for reducing unnecessary biopsy. Unnecessary biopsy was theoretically reduced by 67.86% with the DLM in BI-RADS 4a patients. Zhu et al. (30) developed a DLM based on breast MRIs that showed some predictive value for molecular subtypes. However, these researchers only considered the distinction between the luminal A subtype and all other subtypes. Unlike their model, our model can differentiate each molecular subtype and guide individualized treatment. To the best of our knowledge, this is the first study to apply a DLM to the prediction of molecular subtypes using ultrasound images.

The DLM is better than traditional methods in identifying benign and malignant breast tumors. It performs well with high AUC values and other indicators and reduces the burden of radiologists (31). DLMs do not require time-consuming tumor boundary labeling, which is a necessary step for traditional methods. In addition, the DLM can make better use of the hidden information around the tumor, which is ignored by traditional methods.

Currently, most studies use statistical analysis to obtain low-dimensional features of breast ultrasound images for molecular classification. These low-dimensional features are easily affected by the number and quality of the samples collected, making it difficult to mine and quantify the relationships between images and subtypes (32). However, deep learning methods can extract
abstract features. All extracted features are high-dimensional features related to molecular classification. Although difficult to visualize, molecular classification is important and can greatly improve recognition accuracy.

There are limitations in our study. First, the training set data came from one hospital, and we did not summarize the basic information on patients and tumors. Second, regardless of the training, test or external test sets, the sample size was small. Thus, these results need to be validated with a larger cohort to determine the value of our model in clinical practice. Third, because the study was retrospective, all patients underwent surgical treatment. However, there are many women who have a BI-RADS categorization with certain malignant potential who choose observation instead of surgical treatment. This factor may be one of the reasons why our study did not achieve a better result.

CONCLUSION

We demonstrated that our DLM can recognize breast tumors and predict molecular subtypes with high accuracy based solely on ultrasound images, which may make DLM an effective alternative to clinical biopsy. It is necessary to cooperate with other institutions to expand the dataset to better confirm our model and make it an important decision-making tool with great potential in clinical application.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

This study was approved by the Institutional Review Board of Harbin Medical University Cancer Hospital. Because of its retrospective nature, the written informed consent of patients was exempted.

AUTHOR CONTRIBUTIONS

XZ, YaZ, HM, and DP conceived and designed the study. WC, HJ, SL, and JH collected the clinical and imaging data. HL, JL, and YL performed image preprocessing. XZ, CW, YuZ, DL, YaZ, HM, and DP performed the data interpretation and the statistical analysis. All authors approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (82073410), Heilongjiang Province Applied Technology Research and Development (GA20C016), and the Haiyan Research Foundation (JJZD2020-08).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.623506/full#supplementary-material

REFERENCES

1. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. (2014) 15:e279–89. doi: 10.1016/S1470-2045(13)70567-9
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492
3. Nie K, Su MY, Chau MK, Chan S, Nguyen H, Tseng T, et al. Age- and race-dependence of the fibroglandular breast density analyzed on 3D MRI. Med Phys. (2010) 37:2770–6. doi: 10.1118/1.3426317
4. Li E, Guida JL, Tian Y, Sung H, Koka H, Li M, et al. Associations between mammographic density and tumor characteristics in Chinese women with breast cancer. Breast Cancer Res Treat. (2019) 177:527–36. doi: 10.1007/s10549-019-05325-6
5. Zhou C, He J, Li J, Fan J, Zhang B, Yang H, et al. A nation-wide multicenter 10-year (2008–2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. PLoS One. (2014) 9:e100159. doi: 10.1371/journal.pone.0100159
6. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. (2015) 521:436–44. doi: 10.1038/nature14539
7. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima H, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. (2010) 34:2308–24. doi: 10.1007/s00268-010-0683-1
8. Zhang X, Zhao L, Wei W, You Z, Ou X, Sun M, et al. Parallel analyses of somatic mutations in plasma circulating tumor DNA (ctDNA) and matched tumor tissues in early-stage breast cancer. Clin Cancer Res. (2019) 25:6546–53. doi: 10.1158/1078-0432.CCR-18-0455
8. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. (2015) 521:436–44. doi: 10.1038/nature14539
9. Zhou D, Tien F, Tian X, Sun L, Huang X, Zhao F, et al. Diagnostic evaluation of a deep learning model for optical diagnosis of colorectal cancer. Nat Commun. (2020) 11:2961. doi: 10.1038/s41467-020-16777-6
10. Song Y, Zhang YD, Yan X, Liu H, Zhou M, Hu B, et al. Computer-aided diagnosis of prostate cancer using a deep convolutional neural network from multiparametric MRI. J Magn Reson Imaging. (2018) 48:1570–7. doi: 10.1002/jmri.26047
11. Wang CJ, Hamm CA, Savic LJ, Ferrante M, Schobert I, Schlachter T, et al. Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using radiologic imaging features. Eur Radiol. (2019) 29:3348–57. doi: 10.1007/s00330-019-06214-8
12. Xiong H, Lin P, Yu JG, Ye J, Xiao L, Tao Y, et al. Computer-aided diagnosis of laryngeal cancer via deep learning based on laryngoscopic images. EBioMedicine. (2019) 48:92–9. doi: 10.1016/j.ebiom.2019.08.075
13. Pang S, Yu Z, Organ MA. A novel end-to-end classifier using domain transferred deep convolutional neural networks for biomedical images. Comput Methods Programs Biomed. (2017) 140:283–93. doi: 10.1016/j.cmpb.2016.12.019
14. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. (2000) 406:747–52. doi: 10.1038/35021093
15. Wu T, Li J, Wang D, Leng X, Zhang L, Li Z, et al. Identification of a correlation between the sonographic appearance and molecular subtype of invasive breast cancer: a review of 311 cases. Clin Imaging. (2019) 53:179–85. doi: 10.1016/j.clinimag.2018.10.020
Zhang et al. Deep Learning in Breast Cancer

16. Celebi F, Pilanci KN, Ordu C, Agacayak F, Alco G, Ilgun S, et al. The role of ultrasonographic findings to predict molecular subtype, histologic grade, and hormone receptor status of breast cancer. *Diagn Interv Radiol.* (2015) 21:448–53. doi: 10.5152/dir.2015.14515

17. Zhang L, Li J, Xiao Y, Cui H, Du G, Wang Y, et al. Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision. *Sci Rep.* (2015) 5:11085. doi: 10.1038/srep11085

18. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triple-negative breast cancer: correlation between imaging and pathological findings. *Eur Radiol.* (2010) 20:1111–17. doi: 10.1007/s00330-009-1656-3

19. Irshad A, Leddy R, Pisano E, Baker N, Lewis M, Ackerman S, et al. Assessing the role of ultrasound in predicting the biological behavior of breast cancer. *AJR Am J Roentgenol.* (2013) 200:284–90. doi: 10.2214/AJR.12.8781

20. Boisserie-Lacroix M, Macgrogan G, Debled M, Ferron S, Asad-Syed M, McKelvie-Sebileau P, et al. Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers. *Oncologist.* (2013) 18:802–11. doi: 10.1634/theoncologist.2013-0380

21. Chollet F. Xception: deep learning with depthwise separable convolutions. In: 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR). Honolulu, HI (2017).

22. Li X, Zhang S, Zhang Q, Wei X, Pan Y, Zhao J, et al. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study. *Lancet Oncol.* (2019) 20:193–201. doi: 10.1016/S1470-2247(18)30762-9

23. Wang S, Wang R, Zhang S, Li R, Fu Y, Sun X, et al. 3D convolutional neural network for differentiating pre-invasive lesions from invasive adenocarcinomas appearing as ground-glass nodules with diameters <3 cm using HRCT. *Quart Imaging Med Surg.* (2018) 8:491–9. doi: 10.21037/qims.2018.06.03

24. He Y, Guo J, Ding X, van Ooijen PMA, Zhang Y, Chen A, et al. Convolutional neural network to predict the local recurrence of giant cell tumor of bone after curettage based on pre-surgery magnetic resonance images. *Eur Radiol.* (2019) 29:5441–51. doi: 10.1007/s00330-019-06082-2

25. Moon WK, Lee YW, Ke HH, Lee SH, Huang CS, Chang RF. Computer-aided diagnosis of breast ultrasound images using ensemble learning from convolutional neural networks. *Comput Methods Programs Biomed.* (2020) 190:105361. doi: 10.1016/j.cmpb.2020.105361

26. Tanaka H, Chiu SW, Watanabe T, Kooku S, Yamaguchi T. Computer-aided diagnosis system for breast ultrasound images using deep learning. *Phys Med Biol.* (2019) 64:235013. doi: 10.1088/1361-6560/ab5093

27. Cao Z, Yang G, Chen Q, Chen X, Lv F. Breast tumor classification through learning from noisy labeled ultrasound images. *Med Phys.* (2020) 47:1048–7. doi: 10.1002/mp.13966

28. Zhou Y, Xu J, Liu Q, Li C, Liu Z, Wang M, et al. A radiomics approach with CNN for shear-wave elastography breast tumor classification. *IEEE Trans Biomed Eng.* (2018) 65:1935–42. doi: 10.1109/TBME.2018.2844188

29. Weiss N, Kost H, Homeyer A. Towards interactive breast tumor classification using transfer learning. In: International Conference Image Analysis and Recognition. Cham: Springer (2018). p. 727–36.

30. Zhu Z, Albadawy E, Saha A, Zhang J, Harowicz MR, Mazurowski MA. Deep learning for identifying radiogenomic associations in breast cancer. *Comput Biol Med.* (2019) 109:85–90. doi: 10.1016/j.compbiomed.2019.04.018

31. Xiao T, Liu L, Li K, Qin W, Yu S, Li Z. Comparison of transferred deep neural networks in ultrasonic breast masses discrimination. *Biomed Res Int.* (2018) 2018:4605191. doi: 10.1155/2018/4605191

32. Boisserie-Lacroix M, Bullier B, Hurevent-Labrot G, Ferron S, Lippa N, Mac Grogan G. Correlation between imaging and prognostic factors: molecular classification of breast cancers. *Diagn Interv Imaging.* (2014) 95:227–33. doi: 10.1016/j.diij.2013.12.013

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Li, Wang, Cheng, Zhu, Li, Jing, Li, Hou, Li, Zhao, Mo and Pang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.